Nadia Traficante

20.1k total citations · 1 hit paper
12 papers, 1.6k citations indexed

About

Nadia Traficante is a scholar working on Molecular Biology, Reproductive Medicine and Oncology. According to data from OpenAlex, Nadia Traficante has authored 12 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Reproductive Medicine and 4 papers in Oncology. Recurrent topics in Nadia Traficante's work include Ovarian cancer diagnosis and treatment (7 papers), Ubiquitin and proteasome pathways (3 papers) and BRCA gene mutations in cancer (2 papers). Nadia Traficante is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), Ubiquitin and proteasome pathways (3 papers) and BRCA gene mutations in cancer (2 papers). Nadia Traficante collaborates with scholars based in Australia, United States and Switzerland. Nadia Traficante's co-authors include David D.L. Bowtell, Sián Fereday, Anna DeFazio, Izhak Haviv, Richard W. Tothill, Bianca Locandro, Joshy George, Anna V. Tinker, Daryl Johnson and Robert Brown and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Molecular and Cellular Biology.

In The Last Decade

Nadia Traficante

12 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

2008 1.0k citations Richard W. Tothill, Anna V. Tinker et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Nadia Traficante

Since Specialization

Citations

This map shows the geographic impact of Nadia Traficante's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadia Traficante with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadia Traficante more than expected).

Fields of papers citing papers by Nadia Traficante

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadia Traficante. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadia Traficante. The network helps show where Nadia Traficante may publish in the future.

Co-authorship network of co-authors of Nadia Traficante

This figure shows the co-authorship network connecting the top 25 collaborators of Nadia Traficante. A scholar is included among the top collaborators of Nadia Traficante based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadia Traficante. Nadia Traficante is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	#70 Influence of predictive features on therapy response and survival in high-grade serous ovarian cancer patients by germline BRCA mutation status: an update from the australian ovarian cancer study 2023 ·(unknown), Sián Fereday, Dinuka Ariyaratne, (unknown), Nadia Traficante, Ellen L. Goode, Anna DeFazio, David D.L. Bowtell, Dale W. Garsed	1
2	Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan 2022 ·Journal of Gynecologic Oncology ·Hung‐Hsueh Chou, Sián Fereday, Anna DeFazio, Chih‐Long Chang, David D.L. Bowtell, Heng‐Cheng Hsu, Nadia Traficante, Soo Jeong, Wen‐Fang Cheng, (unknown), (unknown), (unknown), (unknown), (unknown), David Brown, Byoung‐Gie Kim	2
3	Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer 2021 ·Nature Communications ·Aritro Nath, Patrick A. Cosgrove, (unknown), Elizabeth L. Christie, Lance Pflieger, Benjamin J. Copeland, (unknown), (unknown), Ernest Han, Stephen J. Lee, Wenge Wang, Sián Fereday, Nadia Traficante, Ravi Salgia, Theresa L. Werner, Adam L. Cohen, Philip J. Moos, Jeffrey T. Chang, David D.L. Bowtell, Andrea H. Bild	31
4	Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance 2018 ·Gynecologic Oncology ·Kristina Lindemann, Bo Gao, (unknown), Sián Fereday, Catherine Emmanuel, Kathryn Alsop, Nadia Traficante, Paul R. Harnett, David D.L. Bowtell, Anna DeFazio	32
5	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study 2018 ·Cancer Epidemiology Biomarkers & Prevention ·Brian Z. Ring, Rajmohan Murali, Robert A. Soslow, David D.L. Bowtell, Sián Fereday, Anna DeFazio, Nadia Traficante, Catherine J. Kennedy, Alison H. Brand, Raghwa Sharma, Paul R. Harnett, Goli Samimi	3
6	The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer 2016 ·Human Molecular Genetics ·Kristie-Ann Dickson, Alexander J. Cole, Anthony J. Gill, Adele Clarkson, G. Gard, Angela Chou, Catherine J. Kennedy, Beric R. Henderson, (unknown), Sián Fereday, Nadia Traficante, Kathryn Alsop, David D.L. Bowtell, Anna DeFazio, Roderick Clifton‐Bligh, Deborah J. Marsh	27
7	Primary treatment patterns in women recruited to the Australian Ovarian Cancer Study 2012 ·Hereditary Cancer in Clinical Practice ·Jillian A. Hung, Sián Fereday, Paul R. Harnett, Daniel A. Giles, Bo Gao, Nadia Traficante, (unknown), Georgia Chenevix‐Trench, A Green, Penelope M. Webb, David D.L. Bowtell, Anna DeFazio	1
8	Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors 2008 ·Molecular Cancer Research ·Michael S. Anglesio, Jeremy M. Arnold, Joshy George, Anna V. Tinker, Richard W. Tothill, Nicola Waddell, Lisa A. Simms, Bianca Locandro, Sián Fereday, Nadia Traficante, Peter Russell, Raghwa Sharma, Michael J. Birrer, (unknown), Anna DeFazio, Georgia Chenevix‐Trench, David D.L. Bowtell	91
9	Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome breakdown → 2008 ·Clinical Cancer Research ·Richard W. Tothill, Anna V. Tinker, Joshy George, Robert Brown, Stephen B. Fox, Stephen Lade, Daryl Johnson, Melanie Trivett, Dariush Etemadmoghadam, Bianca Locandro, Nadia Traficante, Sián Fereday, Jillian A. Hung, Yoke-Eng Chiew, Izhak Haviv, (unknown), Dorota M. Gertig, Anna DeFazio, David D.L. Bowtell	1041
10	A binding motif for Siah ubiquitin ligase 2003 ·Proceedings of the National Academy of Sciences ·Colin M. House, Ian J. Frew, (unknown), Gerhard Wiche, Nadia Traficante, Edouard C. Nice, Bruno Catimel, David D.L. Bowtell	116
11	The Ubiquitin Ligase Component Siah1a Is Required for Completion of Meiosis I in Male Mice 2002 ·Molecular and Cellular Biology ·Ross A. Dickins, Ian J. Frew, Colin M. House, Moira K. O’Bryan, Andrew J. Holloway, Izhak Haviv, Nadia Traficante, David M. de Kretser, David D.L. Bowtell	91
12	Siah ubiquitin ligase is structurally related to TRAF and modulates TNF-α signaling 2001 ·Nature Structural Biology ·Galina Polekhina, Colin M. House, Nadia Traficante, Joel P. Mackay, Frédéric Relaix, David Sassoon, Michael W. Parker, David D.L. Bowtell	124

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact